PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Both companies show declining cash positions (-10.40% vs AGEN's -54.28%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Below half of AGEN's -54.28%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AGEN's 77.89%. David Dodd sees a leaner approach to short-term items.
-10.80%
Below half of AGEN's -49.23%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.91%
≥ 1.5x AGEN's -0.54%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Less than half of AGEN's -47.22%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-8.44%
≥ 1.5x AGEN's -2.01%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Similar yoy to AGEN's -11.52%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Less than half of AGEN's 18.22%. David Dodd sees fewer expansions in other current obligations.
-12.74%
Above 1.5x AGEN's -5.92%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Less than half of AGEN's -82.66%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Less than half of AGEN's -50.76%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
≥ 1.5x AGEN's -1.16%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
Below half AGEN's 80.98%. Michael Burry sees potential underperformance in building shareholder capital.
-10.73%
Similar yoy to AGEN's -11.52%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Less than half of AGEN's -43.10%. David Dodd sees less overall debt expansion vs. competitor.
10.43%
Less than half of AGEN's -34.79%. David Dodd sees better deleveraging or stronger cash buildup than competitor.